NSCLC
Conditions
Interventions
Sponsors
Eligibility
Inclusion criteria
Inclusion criteria: 1.Aged 18-75 years (including 18 and 75 years), with no gender restriction; 2.Patients with stage IIIB/IIIC or IV NSCLC who are ineligible for radical surgery or radiotherapy and have disease progression after treatment with third-generation TKIs; 3.Having at least 1 measurable lesion (according to RECIST 1.1); 4.Patients can tolerate conventional drug therapies within the screening scope of PTC and have no severe underlying diseases such as cardiopulmonary diseases; 5.Sufficient fresh samples for cell culture can be obtained, and lung biopsy is planned in routine diagnosis and treatment. Priority is given to primary pulmonary lesions;alternatively, malignant pleural effusion, superficial lymph nodes, subcutaneous metastases, intrapulmonary metastases, hepatic metastases, etc. can also be selected; 6.ECOG performance status = 2; 7.Expected survival time of no less than 6 months; 8.Subjects (or their legal representatives) understand and voluntarily sign the informed consent form.
Exclusion criteria
Exclusion criteria: 1.Patients with a history of other previously diagnosed malignant tumors; 2.Patients with uncontrolled comorbidities, including but not limited to: symptomatic congestive heart failure, unstable angina pectoris and myocardial infarction, uncontrolled grade III hypertension, hepatic insufficiency, renal insufficiency, uncontrolled blood glucose due to diabetes, arrhythmia, mental illness or social conditions, etc. 3.Patients with known allergies to the ingredients of the drugs used; 4.Other circumstances deemed inappropriate for participation in the study by the researcher.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Objective response rate,ORR; | — |
Secondary
| Measure | Time frame |
|---|---|
| progression-free survival; | — |
Countries
China
Contacts
Beijing Cancer Hospital